- Home
- WRBY vs MNKD Comparison
WRBY vs MNKD Comparison
Compare WRBY & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WRBY | MNKD |
|---|---|---|
| Founded | 2010 | 1991 |
| Country | United States | United States |
| Employees | N/A | 407 |
| Industry | Ophthalmic Goods | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.8B |
| IPO Year | 2021 | 2004 |
Fundamental Metrics
Financial Performance| Metric | WRBY | MNKD |
|---|---|---|
| Price | $27.05 | $5.98 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 6 |
| Target Price | ★ $25.43 | $10.08 |
| AVG Volume (30 Days) | ★ 5.5M | 2.8M |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 23.47 |
| EPS | 0.00 | ★ 0.10 |
| Revenue | ★ $850,580,000.00 | $313,787,000.00 |
| Revenue This Year | $15.47 | $21.54 |
| Revenue Next Year | $12.84 | $22.21 |
| P/E Ratio | $10,724.35 | ★ $60.37 |
| Revenue Growth | 14.55 | ★ 17.43 |
| 52 Week Low | $13.63 | $3.38 |
| 52 Week High | $31.00 | $7.07 |
Technical Indicators
Market Signals| Indicator | WRBY | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 65.57 | 64.93 |
| Support Level | $25.78 | $5.59 |
| Resistance Level | $31.00 | $6.01 |
| Average True Range (ATR) | 1.94 | 0.20 |
| MACD | 0.83 | 0.05 |
| Stochastic Oscillator | 67.43 | 80.36 |
Price Performance
Historical ComparisonAbout WRBY Warby Parker Inc.
Warby Parker Inc is a mission-driven, lifestyle brand that operates at the intersection of design, technology, healthcare, and social enterprise. The company predominantly derives revenue from the sales of eyewear products, optical services, and accessories. The firm sells products and services through its stores, website, and mobile apps. Revenue generated from eyewear products includes the sales of prescription and non-prescription optical glasses and sunglasses, contact lenses, eyewear accessories, and expedited shipping charges.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.